CIK: 0001540358
Total reported value
$1.3B
Reporting period: 2026-03-31 · Number of holdings: 16
a16z Capital Management, L.L.C. disclosed 16 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $1.3B and a quarterly turnover rate of 40.1%.
Browse other institutions with $1B to $10B AUMBrowse other institutions starting with "A"
a16z Capital Management, L.L.C.'s disclosed holdings carry a Herfindahl concentration index of 0.177 — mathematically equivalent to about 6 equally-sized positions, well below its 16 actual disclosed holdings. That gap points to a strategy built around a small core of high-conviction bets rather than broad diversification.
Position sizes vary widely across the portfolio (a coefficient of variation of 1.40), with a handful of outsized bets alongside many smaller positions.
Recent activity leans toward adding more aggressively to already-large existing positions than to newly initiated ones (a 28.5 percentage-point tilt) — a pattern consistent with a momentum-following approach.
Sector classification currently covers about 21% of this portfolio's disclosed value; the remainder includes holdings (e.g. unmapped tickers, options, or other security types) not yet covered by our sector mapping.
Trim FIG
-1.4% -$268.6M
Add NAUT
0.0% $34.1M
Add ERAS
0.0% $35.7M
Add RVMD
0.0% $16.2M
Add BIOA
0.0% $12.5M
Trim OMDA
-33.3% -$25.6M
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | NAVN | Navan Inc-cl A | Stock-Other | 28.95% | -0.45% | +3.76% | |
| 2 | FIG | Figma Inc-cl A | Stock-Other | 26.23% | -12.20% | -1.45% | |
| 3 | META | Meta Platforms Inc-class A | Stock-Comm Services | 9.42% | +0.54% | — | |
| 4 | RVMD | Revolution Medicines INC | Stock-Healthcare | 6.94% | +2.30% | — | |
| 5 | NAUT | Nautilus Biotechnology INC | Stock-Other | 5.31% | +3.13% | — | |
| 6 | XYZ | Block INC | Stock-Financials | 4.74% | +0.55% | — | |
| 7 | BIOA | Bioage Labs INC | Stock-Other | 4.38% | +1.59% | — | |
| 8 | MAZE | Maze Therapeutics INC | Stock-Other | 3.94% | -0.52% | — | |
| 9 | ERAS | Erasca INC | Stock-Other | 3.59% | +2.92% | — | |
| 10 | DMRA | Damora Therapeutics INC | Stock-Other | 2.48% | +2.48% | NEW | |
| 11 | OMDA | Omada Health INC | Stock-Other | 2.25% | -1.21% | -33.33% | |
| 12 | CAMP | Camp4 Therapeutics CORP | Stock-Other | 0.73% | -0.09% | — | |
| 13 | AKTS | Aktis Oncology INC | Stock-Other | 0.58% | +0.58% | NEW | |
| 14 | BTGO | Bitgo Holdings Inc-cl A | Stock-Other | 0.42% | +0.42% | NEW | |
| 15 | DNA | Ginkgo Bioworks Holdings INC | Stock-Other | 0.05% | -0.01% | — | |
| 16 | ✓ | Heritage Distilling Hldg | Stock-Other | — | — | NEW |
Performance for Q3 2026
+36.6%
Performance Last 4 Quarters
+41.7%
Based on 85% of reported portfolio value with available pricing
| Period | Holdings | Total value | Stability | Top holdings |
|---|---|---|---|---|
| 2026-03-31 | 16 | $1.3B | 40 | |
| 2025-12-31 | 13 | $1.6B | 61 | |
| 2025-09-30 | 11 | $1.4B | 100 | |
| 2025-06-30 | 10 | $312.9M | 0 | |
| 2025-03-31 | 13 | $700.9M | 0 | |
| 2024-12-31 | 12 | $745.3M | 0 | |
| 2024-09-30 | 13 | $1.1B | 0 | |
| 2024-06-30 | 13 | $1.2B | 0 | |
| 2024-03-31 | 13 | $1.4B | 0 | |
| 2023-12-31 | 16 | $1.6B | 0 |
a16z Capital Management, L.L.C.'s most significant position changes for 2026-03-31: New buy: Damora Therapeutics INC (DMRA); New buy: Aktis Oncology INC (AKTS); New buy: Bitgo Holdings Inc-cl A (BTGO); Sold out: Heritage Commerce CORP (XHC); New buy: Heritage Distilling Hldg.
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | NAUT | Nautilus Biotechnology INC | +3.1% | — | Unchanged |
| 2 | ERAS | Erasca INC | +2.9% | — | Unchanged |
| 3 | RVMD | Revolution Medicines INC | +2.3% | — | Unchanged |
| 4 | BIOA | Bioage Labs INC | +1.6% | — | Unchanged |
| 5 | XYZ | Block INC | +0.6% | — | Unchanged |
| 6 | META | Meta Platforms Inc-class A | +0.5% | — | Unchanged |
| 7 | DNA | Ginkgo Bioworks Holdings INC | 0% | — | Unchanged |
| 8 | CAMP | Camp4 Therapeutics CORP | -0.1% | — | Unchanged |
| 9 | NAVN | Navan Inc-cl A | -0.5% | +3.76% | Add |
| 10 | MAZE | Maze Therapeutics INC | -0.5% | — | Unchanged |
| 11 | OMDA | Omada Health INC | -1.2% | -33.33% | Trim |
| 12 | FIG | Figma Inc-cl A | -12.2% | -1.45% | Trim |
| 13 | DMRA | Damora Therapeutics INC | — | NEW | New buy |
| 14 | AKTS | Aktis Oncology INC | — | NEW | New buy |
| 15 | BTGO | Bitgo Holdings Inc-cl A | — | NEW | New buy |
| 16 | XHC | Heritage Commerce CORP | — | EXIT | Sold out |
| 17 | ✓ | Heritage Distilling Hldg | — | NEW | New buy |
| Period | Filed | Type | EDGAR |
|---|---|---|---|
| 2026-03-31 | 2026-05-15 | 13F-HR | View on EDGAR |
| 2025-12-31 | 2026-02-17 | 13F-HR | View on EDGAR |
| 2025-09-30 | 2025-11-14 | 13F-HR | View on EDGAR |
| 2025-06-30 | 2025-08-14 | 13F-HR | View on EDGAR |
| 2025-03-31 | 2025-05-15 | 13F-HR | View on EDGAR |
| 2024-12-31 | 2025-02-12 | 13F-HR | View on EDGAR |
| 2024-09-30 | 2024-11-13 | 13F-HR | View on EDGAR |
| 2024-06-30 | 2024-08-13 | 13F-HR | View on EDGAR |
| 2024-03-31 | 2024-05-15 | 13F-HR | View on EDGAR |
| 2023-12-31 | 2024-05-15 | Amendment | View on EDGAR |
| 2023-12-31 | 2024-02-14 | 13F-HR | View on EDGAR |
Institutions with a similar AUM
CIK 0001158202
Total reported value
$1.3B
172 stks
2026-03-31
AUM within 0.0% of this institution
CIK 0001093589
Total reported value
$1.3B
100 stks
2026-03-31
AUM within 0.1% of this institution
CIK 0001810720
Total reported value
$1.3B
211 stks
2026-03-31
AUM within 0.1% of this institution
Institutions with overlapping top holdings
CIK 0002056786
Total reported value
$120.4M
6 stks
2026-03-31
2 of the top 5 holdings overlap, including Revolution Medicines INC
CIK 0002113747
Total reported value
$228.8M
4 stks
2026-03-31
2 of the top 5 holdings overlap, including Navan Inc-cl A
CIK 0000021175
Total reported value
$235.2M
15 stks
2026-03-31
1 of the top 5 holdings overlap, including Meta Platforms Inc-class A